The authors explained that ultraviolet light and carcinogenic chemicals may activate some carcinogenic pathways enabling keratinocytes to bypass the IGF1 signaling; and that rosiglitazone may possibly inhibit the development of skin cancer through activation of AMP-activated protein kinase with subsequent inhibition of IGF1-induced mammalian target of rapamycin activity and phosphorylation of p70S6 kinase [9]. The gene discussed is MTOR; the disease is skin neoplasm.